Sandbox:risk

INSS stage 1 Irrespective of age Irrespective of grade Irrespective of molecular pathway

Low risk neuroblastoma patients

INSS stage 2A/2B (>50% resected) Irrespective of age Irrespective of grade MYCN not amplified

INNS stage 4S <365 days of age Favorable histology DNA index >1 MYCN not amplified

INSS stage 1 Irrespective of age Irrespective of grade Irrespective of molecular pathway

INSS stage 2A/2B (>50% resected) Irrespective of age Irrespective of grade MYCN not amplified

Intermediate risk neuroblastoma patients (group 1)

INNS stage 4S <365 days of age Favorable histology DNA index >1 MYCN not amplified

INNS stage 4S <365 days of age Favorable histology DNA index >1 MYCN not amplified

Intermediate risk neuroblastoma patients include:

Group 1

Patients with stage 2A/2B (<50% resected or Bx only) tumor, 0-12 years of age, irrespective of the grade, MYCNnot amplified Patients with stage 3 tumor, <365 days of age, favorable histology, DNA index >1, MYCN not amplified Patients with stage 3 tumor, 1-12 years of age, favorable histology, MYCNnot amplified Patients with symptomatic stage 4S, <365 days of age, favorable histology, DNA index >1, MYCNnot amplified

Group 2

Patients with stage 3 tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified Patients with stage 4 tumor, <365 days of age, favorable histology, DNA index >1, MYCN not amplified Patients with stage 4S tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified

Group 3

Patients with stage 4 tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified Patients with stage 3 tumor, 365-547 days of age, unfavorable histology, MYCN not amplified Patients with stage 4 tumor, 365-547 days of age, favorable histology, DNA index >1, MYCN not amplified